Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of OvaScience, Inc. (“OvaScience” or the “Company”) (NASDAQ:OVAS). The investigation concerns possible violations of federal securities laws and focuses on certain statements issued by OvaScience concerning the Company’s business and operations.
OvaScience is engaged in the discovery, development and commercialization of new treatments for infertility. The Company's first fertility treatment is AUGMENT – an assisted reproductive technology which complements the existing standard of practice for an in vitro fertilization cycle. The investigation is related to allegations that the Company misrepresented or failed to disclose material information concerning the clinical development of AUGMENT and regulatory concerns raised by the Food and Drug Administration that could potentially threaten or delay FDA approval of AUGMENT.
On September 10, 2013, OvaScience disclosed that it was suspending enrollment of the AUGMENT clinical trial in the United States after the Company received a letter from the FDA questioning whether AUGMENT qualified for reduced regulatory oversight and advising the Company to file an Investigational New Drug application. Following this news, OvaScience shares dropped or more than 23%, or $3.325 per share, to close at $10.95 per share on September 11, 2013.
If you purchased OvaScience securities between February 25, 2013 and September 10, 2013, or if you are a long-term shareholder of OvaScience and would like to learn more about these or other potential claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to email@example.com, or visit our website at www.howardsmithlaw.com.